About
Executive/senior manager with 20 years of experience in the bio-pharmaceutical industry.…
Activity
-
Biopharma acquisitions H1/24 # of deals and cumulative deal volume: 26 deals*, at least $34bn Top 5 deals by volume: · Alpine Immune…
Biopharma acquisitions H1/24 # of deals and cumulative deal volume: 26 deals*, at least $34bn Top 5 deals by volume: · Alpine Immune…
Liked by David White
-
I am thrilled to announce that I have joined Next Insurance as the Office Manager of the Waltham Office! I am beyond excited for the opportunity to…
I am thrilled to announce that I have joined Next Insurance as the Office Manager of the Waltham Office! I am beyond excited for the opportunity to…
Liked by David White
-
The motor is always running, cells not on a WFH schedule are cranking out Molecular Machines. #biotechnology
The motor is always running, cells not on a WFH schedule are cranking out Molecular Machines. #biotechnology
Liked by David White
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
-
Boston University
Dissertation Research; ; NIH trainee, laboratory of Dr. Thomas Gilmore
thesis topic: studies on the mechanism of transformation and immortalization of lymphoid cells by the v-rel oncogene, a member of the NF-*B family of transcription factors -
-
-
Other similar profiles
Explore more posts
-
Els Saesen
What if you could de-risk your lead candidate earlier in the project, using human proteins & primary human tissues? Discovery | Charles River have a streamlined and efficient multi-disciplinary approach given you highly valuable insights. Contact me to discuss how our process can help your project! #drugdiscovery #derisking Nick Brown Lisa Scandiuzzi, PhDGemma Moiset, Namrata Jayanth, Omar Aziz
-
Nayoung K. D. Kim
At PROTEINA, our recent publication on bioRxiv demonstrates the groundbreaking capabilities of the Single molecule Protein Interaction Detection (SPID) platform in advancing antibody development with finely-tuned affinities. I’d like to highlight two groundbreaking aspects from this study that are particularly significant: 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐌𝐨𝐝𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 𝐢𝐧 𝐂𝐃𝐑𝐬: Our targeted edits within the Complementarity Determining Regions (CDRs) of antibodies have led to the discovery of affinity-enhancing mutations. These modifications have successfully produced sub-nanomolar affinity candidates, setting a new benchmark for antibody affinity maturation. 𝐇𝐢𝐠𝐡-𝐭𝐡𝐫𝐨𝐮𝐠𝐡𝐩𝐮𝐭 𝐂𝐡𝐚𝐫𝐚𝐜𝐭𝐞𝐫𝐢𝐳𝐚𝐭𝐢𝐨𝐧: The ability of PROTEINA’s SPID platform to rapidly characterize over 3,000 antibodies weekly is revolutionizing our understanding of antibody-antigen interactions. This capability is crucial for accelerating the development of tailored therapeutic interventions. Almost forgot to mention this! Keep an eye on the future contributions of PROTEINA’s Jihye Jo well!
4 Comments -
Max Brennan, MSc
🎉 The BioHub Episode with Rob Etherington, CEO of Clene Nanomedicine, Inc. is Live! 🎉 Rob dives into Clene's groundbreaking work against neurodegenerative diseases, predicted by the WHO to be the second leading cause of death in the coming decades. In this episode, you'll hear about: 🧬 Clene’s groundbreaking nanotechnology 🌍 The critical importance of their mission 🧠 Why understanding the brain remains one of the biggest challenges in medicine Don’t miss out on this enlightening episode! Click the link in the comments to watch the full episode. Remember to like, share, and subscribe to The BioHub Podcast! 🚀 Let us know your thoughts in the comments below. #TheBioHub #Podcast #Biotech #Innovation #NeurodegenerativeDiseases #Nanomedicine #CleneNanomedicine #RobEtherington #Healthcare #FutureOfMedicine
2 Comments -
Jaehyuk Imm
🎉 Huge congratulations to Orum Therapeutics for their deal yesterday! Vertex bolts on Orum's Degrader-Antibody Conjugate(DAC) conditioning agents to ImmunoGen's ADC conditioner, acquired in March 2023. But what drives Vertex to explore novel conditioner candidates? Traditional conditioning agents are poorly tolerated and have posed significant challenges for Hematopoietic Stem Cell (#HSC) Cell and Gene Therapies (CGT), such as Vertex's Casgevy. These hurdles are now being addressed by novel, less aggressive conditioners, as above. For instance, companies like Actinium Pharmaceuticals are also advancing novel conditioning agents in this space. Thus, improved conditioning agents will play a crucial role in expanding the application of HSC CGT. Another critical challenge in HSC CGT is effective #mobilization. Emerging CGTs often require a higher yield of HSCs than conventional HSC transplantation in cancer. When it comes to in vivo approaches, having more HSCs available in peripheral blood will be critical since ex vivo collection and engineering are not feasible. Thus, there is a growing demand for enhanced HSC mobilizers in this evolving field. Here comes #GPC201, a potential best/fastest-in-class HSC mobilizer currently in phase 2 clinical trials in the US. It is demonstrating superior features for HSC transplantation in multiple myeloma. As the universe of various CGT pipelines expands rapidly, GPC201 is poised to showcase its full potential. I eagerly anticipate the transformative impact of pairing GPC201 with novel conditioning agents to enhance patients' HSC transplantation experiences. Curious about GPC201? 👉👉👉 GPCR Therapeutics
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named David White in United States
-
David White
-
David White
Chief Growth Officer at Referralogix
-
David White
-
David White
-
David White
Vice President - Infrastructure and Operations at Associated Electric Inc.
4932 others named David White in United States are on LinkedIn
See others named David White